{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:51:10Z","timestamp":1791924670685,"version":"4.3.4"},"reference-count":20,"publisher":"Georg Thieme Verlag KG","issue":"06","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Else Kr\u00f6ner-Fresenius Stiftung","award":["2013_A182, 2015_A171"],"award-info":[{"award-number":["2013_A182, 2015_A171"]}]},{"name":"Else Kr\u00f6ner-Fresenius Stiftung","award":["2019_A104"],"award-info":[{"award-number":["2019_A104"]}]},{"name":"Deutsche Forschungsgemeinschaft to F.B.","award":["BE2177\/13-1"],"award-info":[{"award-number":["BE2177\/13-1"]}]},{"name":"European Research Council","award":["694913"],"award-info":[{"award-number":["694913"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:p>Primary aldosteronism (PA) is characterized by hypertension caused by inappropriately\nhigh adrenal aldosterone secretion, consecutively low plasma renin, and an elevated\naldosterone to renin ratio. It is nowadays the universally accepted main cause of\nendocrine hypertension. According to the most recent epidemiological data, PA is\npresent in 5.8% of unselected hypertensives in primary care,\n6\u201312% of hypertensives treated in hypertension centers, and up to\n30% in subjects with resistant hypertension 1. Despite this high prevalence, a recent survey demonstrated that\nscreening for PA is not universally followed. Renin and aldosterone measurements,\nthe basis for PA screening, are currently performed by only 7% of general\npractitioners in Italy and 8% in Germany 2. Accordingly, the prevalence of PA was low with 1% among\nhypertensives in Italy and 2% in Germany. In a retrospective cohort study of\n4660 patients with resistant hypertension in California the screening rate for PA\nwas 2.1% 3. Based on these data, it\nis clear that we still miss the majority of PA cases, despite advances in diagnosis\nand therapy.<\/jats:p>","DOI":"10.1055\/a-1156-9926","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T22:31:17Z","timestamp":1592346677000},"page":"345-346","source":"Crossref","is-referenced-by-count":5,"title":["Progress in Primary Aldosteronism 2019: New Players on the\nBlock?"],"prefix":"10.1055","volume":"52","author":[{"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, Klinikum der Universit\u00e4t\nM\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, Klinikum der Universit\u00e4t\nM\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy Ann","family":"Williams","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik IV, Klinikum der Universit\u00e4t\nM\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"101365","DOI":"10.1016\/j.beem.2019.101365.","article-title":"Prevalence, diagnosis and outcomes of treatment for primary aldosteronism","author":"Y Yang","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/HJH.0000000000001088","article-title":"Guidelines for primary aldosteronism: Uptake by primary care physicians in\nEurope","volume":"34","author":"P Mulatero","year":"2016","journal-title":"J Hypertens"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.119.14359","article-title":"Screening rates for primary aldosteronism in resistant","volume":"75","author":"G Jaffe","year":"2020","journal-title":"hypertension: A cohort study. Hypertension"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared\nwith essential hypertension: A systematic review and meta-analysis","volume":"6","author":"S Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fendo.2020.00121","article-title":"Long-Term mortality for patients of primary aldosteronism compared with\nessential hypertension: A systematic review and meta-analysis","volume":"11","author":"Z Meng","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1055\/a-1134-4980","article-title":"Hypokalemia and the prevalence of primary aldosteronism","volume":"52","author":"S Gruber","year":"2020","journal-title":"Horm Metab Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1055\/a-1141-5989","article-title":"Atrial fibrillation in primary aldosteronism","volume":"52","author":"C-T Pan","year":"2020","journal-title":"Horm Metab Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/a-1133-7255","article-title":"Primary aldosteronism and obstructive sleep apnea: casual association or\npathophysiological link?","volume":"52","author":"A Pecori","year":"2020","journal-title":"Horm Metab Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/a-1141-3526","article-title":"Developments in primary aldosteronism subtyping using steroid profiling","volume":"52","author":"T Wannachalee","year":"2020","journal-title":"Horm Metab Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/a-1120-8647","article-title":"Angiotensin II type 1 receptor autoantibodies in primary aldosteronism","volume":"52","author":"L S Meyer","year":"2020","journal-title":"Horm Metab Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1055\/a-1116-2407","article-title":"Salt appetite and its effects on cardiovascular risk in primary\naldosteronism","volume":"52","author":"C Adolf","year":"2020","journal-title":"Horm Metab Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1055\/a-1116-2366","article-title":"MicroRNAs and adrenocortical tumors: Where do we stand on primary\naldosteronism?","volume":"52","author":"Z T\u00f6mb\u00f6l","year":"2020","journal-title":"Horm Metab Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1055\/a-1164-1944","article-title":"The impact of glucocorticoid co-secretion in primary aldosteronism on thyroid\nautoantibody titers during the course of disease","volume":"52","author":"L Handgriff","year":"2020","journal-title":"Horm Metab Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/a-1119-1063","article-title":"Role of mast cells in the control of aldosterone secretion","volume":"52","author":"A-G Lopez","year":"2020","journal-title":"Horm Metab Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1055\/a-1139-2079","article-title":"Immunohistochemistry of the human adrenal CYP11B2 in normal individuals and in\npatients with primary aldosteronism","volume":"52","author":"C E Gomez-Sanchez","year":"2020","journal-title":"Horm Metab Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/a-1128-0421","article-title":"The potential role of aldosterone-producing cell clusters in adrenal\ndisease","volume":"52","author":"J S Lim","year":"2020","journal-title":"Horm Metab Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/a-1129-6947","article-title":"In situ metabolite mass spectrometry imaging: New insights into the adrenal\ngland","volume":"52","author":"F Li","year":"2020","journal-title":"Horm Metab Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1055\/a-1157-0511","article-title":"The effect of extracellular calcium metabolism on aldosterone biosynthesis in\nphysiological and pathological status","volume":"52","author":"X Gao","year":"2020","journal-title":"Horm Metab Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1055\/a-1139-1783","article-title":"Age, gender, and body mass index as determinants of surgical outcome in primary\naldosteronism","volume":"52","author":"M Naruse","year":"2020","journal-title":"Horm Metab Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1055\/a-1120-8623","article-title":"Primary aldosteronism: Where are we now? Where to from here?","volume":"52","author":"J W Funder","year":"2020","journal-title":"Horm Metab Res"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1156-9926.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:29:25Z","timestamp":1661300965000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1156-9926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":20,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2020,6,16]]},"published-print":{"date-parts":[[2020,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1156-9926","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}